Pontiano Kaleebu
Born1960 (age 63–64)
Uganda
NationalityUgandan
CitizenshipUganda
Alma materMakerere University
(Bachelor of Medicine and Bachelor of Surgery)
University of London
(Diploma in Immunology)
(Doctor of Philosophy in Immunology)
Occupation(s)Physician, Academic
Clinical Immunologist
HIV/AIDS Researcher
and Medical Administrator
Years active1995 – present
Known forProfessional competence
TitleExecutive Director of Uganda Virus Research Institute

Pontiano Kaleebu is a Ugandan physician, clinical immunologist, HIV/AIDS researcher, academic and medical administrator, who is the executive director of the Uganda Virus Research Institute.[1]

He also concurrently serves as the director of the joint clinical research unit owned by the Medical Research Council (United Kingdom), the Uganda Virus Research Institute, and the London School of Hygiene & Tropical Medicine, located in Entebbe, Uganda, carrying on research in infectious, non-communicable and neglected diseases.[1][2]

Background and education

Pontiano Kaleebu was born in Uganda, circa 1960.[3] He attended Jinja Kaloli Primary School, in Wakiso District, where he obtained his Primary Leaving Certificate. He then transferred to St. Mary's College Kisubi, where he undertook his O-Level studies. He completed his A-Level education at Kampala High School, where he obtained his High School Diploma.[3]

He was admitted to Makerere University School of Medicine, where he graduated with a Bachelor of Medicine and Bachelor of Surgery degree in the mid 1980s. He interned at St. Francis Hospital Nsambya, under Dr. Merriam Duggan.[3]

In 1988, Kaleebu was awarded a scholarship to study immunology at the Royal Postgraduate Medical School, at Hammersmith Hospital, in West London, in the United Kingdom. He graduated with a Diploma in Immunology.[3]

While in London, he was offered the opportunity to pursue a doctorate in immunology, by the University of London, on scholarship, under Professor Jonathan Weber, at St Mary's Hospital, London. He completed his PhD program in the mid 1990s.[1][3]

Career

1987, Kaleebu was recruited as a medical research officer at the Uganda Virus Research Institute, by its director, Dr. Sylvester Sempala. Following the completion of his PhD studies, Kaleebu returned to the institute and was appointed as the head of the immunology department. The following year, he joined the joint research programme at the Medical Research Council and the Uganda Virus Research Institute.[3]

Over the years, Dr Kaleebu has become a leading international researcher in the areas of immunology and virology and is a member to the international team that participated the first vaccine trial in Africa against HIV/AIDS. In the late 2000s, he became the director of the Uganda Virus Research Institute in an acting capacity.[3] He was confirmed in that position in the mid-2010s. He is a Professor of immunovirology at the London School of Hygiene and Tropical Medicine.[4]

Other considerations

His main research interests are HIV vaccine research especially understanding HIV diversity and resistance to antiretroviral drugs, as well as the protective immune responses. He is the recipient of numerous Awards including (a) the Scientific Achievement Award from Rotary International, awarded in 2003 (b) the Presidential Science Award 2005/2006 and (c) the Fellowship of Imperial College London, Faculty of Medicine, awarded in 2010 (d) Fellow of the Royal College of Physicians of Edinburgh- FRCP Edin 2016 (e) Fellow of the Academy of Medical Sciences-FMedSci 2020. (f) Fellow of the Uganda National Academy of Science-FUNAS 2021. He has co-authored more than 260 publications in peer reviewed journals.[1] Some of his most cited publications include; Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis (2019),[5] HIV subtype diversity worldwide (2019),[6] Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania (2019),[7] HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis (2018),[8] Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease (2016),[9] Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study (2016),[10] The African genome variation project shapes medical genetics in Africa (2015),[11] Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis (2015),[12] A KIR B centromeric region present in Africans but not Europeans protects pregnant women from pre-eclampsia (2015),[13] Towards host-directed therapies for tuberculosis (2015),[14] Randomised controlled trials for Ebola: practical and ethical issues (2014),[15] Immune activation alters cellular and humoral responses to yellow fever 17D vaccine (2014),[16] Pregnancy, parturition and preeclampsia in women of African ancestry (2014),[17] Discovery and refinement of loci associated with lipid levels (2013),[18] Common variants associated with plasma triglycerides and risk for coronary artery disease (2013),[19] Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis (2013),[20] High HIV incidence and socio-behavioral risk patterns in fishing communities on the shores of Lake Victoria, Uganda (2012),[21] HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda (2011),[22] Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa (2011),[23] CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa (2009),[24] Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa (2008),[25] Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort (2007),[26] The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis (2004),[27] Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1—positive persons in Uganda (2002),[28] Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort (2001),[29] Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO network for HIV isolation and characterization (1996)[30]

Awards

He received a medal of service from the government of the Republic of Uganda[31]

References

  1. 1 2 3 4 "Profile of Professor Pontiano Kaleebu". Entebbe: Medical Research Council (Uganda). 2018. Retrieved 4 December 2018.
  2. ↑ Ainebyoona, Emmanuel (14 May 2018), "UVRI partners with London school for cancer research", Daily Monitor, Kampala, retrieved 4 December 2018
  3. 1 2 3 4 5 6 7 Kalibbala, Gladys (29 November 2009). "Kaleebu came home to find cure for AIDS". New Vision. Kampala. Retrieved 4 December 2018.
  4. ↑ "Meet Prof. Pontiano Kaleebu: UVRI's new Director". Atlanta: International Association of National Public Health Institutes. 3 August 2016. Retrieved 4 December 2018.
  5. ↑ Hemelaar, Joris; Elangovan, Ramyiadarsini; Yun, Jason; Dickson-Tetteh, Leslie; Fleminger, Isabella; Kirtley, Shona; Williams, Brian; Gouws-Williams, Eleanor; Ghys, Peter D; Abimiku, Alash'le G; Agwale, Simon (1 February 2019). "Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis". The Lancet Infectious Diseases. 19 (2): 143–155. doi:10.1016/S1473-3099(18)30647-9. ISSN 1473-3099. PMID 30509777. S2CID 54485664.
  6. ↑ Bbosa, Nicholas; Kaleebu, Pontiano; Ssemwanga, Deogratius (2019). "HIV subtype diversity worldwide". Current Opinion in HIV and AIDS. 14 (3): 153–160. doi:10.1097/COH.0000000000000534. ISSN 1746-630X. PMID 30882484. S2CID 81977044.
  7. ↑ "Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania". The Journal of Infectious Diseases. Retrieved 26 May 2022.
  8. ↑ Gupta, Ravindra K; Gregson, John; Parkin, Neil; Haile-Selassie, Hiwot; Tanuri, Amilcar; Andrade Forero, Liliana; Kaleebu, Pontiano; Watera, Christine; Aghokeng, Avelin; Mutenda, Nicholus; Dzangare, Janet (1 March 2018). "HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis". The Lancet Infectious Diseases. 18 (3): 346–355. doi:10.1016/S1473-3099(17)30702-8. ISSN 1473-3099. PMC 5835664. PMID 29198909.
  9. ↑ Zanoni, Paolo; Khetarpal, Sumeet A.; Larach, Daniel B.; Hancock-Cerutti, William F.; Millar, John S.; Cuchel, Marina; DerOhannessian, Stephanie; Kontush, Anatol; Surendran, Praveen; Saleheen, Danish; Trompet, Stella (11 March 2016). "Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease". Science. 351 (6278): 1166–1171. Bibcode:2016Sci...351.1166Z. doi:10.1126/science.aad3517. ISSN 0036-8075. PMC 4889017. PMID 26965621.
  10. ↑ Gregson, John; Tang, Michele; Ndembi, Nicaise; Hamers, Raph L; Rhee, Soo-Yon; Marconi, Vincent C; Diero, Lameck; Brooks, Katherine A; Theys, Kristof; Rinke de Wit, Tobias; Arruda, Monica (1 May 2016). "Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study". The Lancet Infectious Diseases. 16 (5): 565–575. doi:10.1016/S1473-3099(15)00536-8. ISSN 1473-3099. PMC 4835583. PMID 26831472.
  11. ↑ Gurdasani, Deepti; Carstensen, Tommy; Tekola-Ayele, Fasil; Pagani, Luca; Tachmazidou, Ioanna; Hatzikotoulas, Konstantinos; Karthikeyan, Savita; Iles, Louise; Pollard, Martin O.; Choudhury, Ananyo; Ritchie, Graham R. S. (2015). "The African Genome Variation Project shapes medical genetics in Africa". Nature. 517 (7534): 327–332. Bibcode:2015Natur.517..327G. doi:10.1038/nature13997. ISSN 1476-4687. PMC 4297536. PMID 25470054. S2CID 4463627.
  12. ↑ Rhee, Soo-Yon; Blanco, Jose Luis; Jordan, Michael R.; Taylor, Jonathan; Lemey, Philippe; Varghese, Vici; Hamers, Raph L.; Bertagnolio, Silvia; Wit, Tobias F. Rinke de; Aghokeng, Avelin F.; Albert, Jan (7 April 2015). "Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis". PLOS Medicine. 12 (4): e1001810. doi:10.1371/journal.pmed.1001810. ISSN 1549-1676. PMC 4388826. PMID 25849352.
  13. ↑ Nakimuli, Annettee; Chazara, Olympe; Hiby, Susan E.; Farrell, Lydia; Tukwasibwe, Stephen; Jayaraman, Jyothi; Traherne, James A.; Trowsdale, John; Colucci, Francesco; Lougee, Emma; Vaughan, Robert W. (20 January 2015). "A KIR B centromeric region present in Africans but not Europeans protects pregnant women from pre-eclampsia". Proceedings of the National Academy of Sciences. 112 (3): 845–850. Bibcode:2015PNAS..112..845N. doi:10.1073/pnas.1413453112. ISSN 0027-8424. PMC 4311823. PMID 25561558.
  14. ↑ Zumla, Alimuddin; Chakaya, Jeremiah; Hoelscher, Michael; Ntoumi, Francine; Rustomjee, Roxana; Vilaplana, Cristina; Yeboah-Manu, Dorothy; Rasolofo, Voahangy; Munderi, Paula; Singh, Nalini; Aklillu, Eleni (2015). "Towards host-directed therapies for tuberculosis". Nature Reviews Drug Discovery. 14 (8): 511–512. doi:10.1038/nrd4696. ISSN 1474-1784. PMID 26184493. S2CID 7418745.
  15. ↑ Adebamowo, Clement; Bah-Sow, Oumou; Binka, Fred; Bruzzone, Roberto; Caplan, Arthur; Delfraissy, Jean-François; Heymann, David; Horby, Peter; Kaleebu, Pontiano; Tamfum, Jean-Jacques Muyembe; Olliaro, Piero (18 October 2014). "Randomised controlled trials for Ebola: practical and ethical issues". The Lancet. 384 (9952): 1423–1424. doi:10.1016/S0140-6736(14)61734-7. ISSN 0140-6736. PMC 4392883. PMID 25390318.
  16. ↑ Muyanja, Enoch; Ssemaganda, Aloysius; Ngauv, Pearline; Cubas, Rafael; Perrin, Helene; Srinivasan, Divya; Canderan, Glenda; Lawson, Benton; Kopycinski, Jakub; Graham, Amanda S.; Rowe, Dawne K. (1 July 2014). "Immune activation alters cellular and humoral responses to yellow fever 17D vaccine". The Journal of Clinical Investigation. 124 (7): 3147–3158. doi:10.1172/JCI75429. ISSN 0021-9738. PMC 4071376. PMID 24911151.
  17. ↑ Nakimuli, Annettee; Chazara, Olympe; Byamugisha, Josaphat; Elliott, Alison M.; Kaleebu, Pontiano; Mirembe, Florence; Moffett, Ashley (1 June 2014). "Pregnancy, parturition and preeclampsia in women of African ancestry". American Journal of Obstetrics and Gynecology. 210 (6): 510–520.e1. doi:10.1016/j.ajog.2013.10.879. ISSN 0002-9378. PMC 4046649. PMID 24184340.
  18. ↑ Consortium, Global Lipids Genetics (2013). "Discovery and refinement of loci associated with lipid levels". Nature Genetics. 45 (11): 1274–1283. doi:10.1038/ng.2797. ISSN 1061-4036. PMC 3838666. PMID 24097068.
  19. ↑ Do, Ron; Willer, Cristen J.; Schmidt, Ellen M.; Sengupta, Sebanti; Gao, Chi; Peloso, Gina M.; Gustafsson, Stefan; Kanoni, Stavroula; Ganna, Andrea; Chen, Jin; Buchkovich, Martin L. (2013). "Common variants associated with plasma triglycerides and risk for coronary artery disease". Nature Genetics. 45 (11): 1345–1352. doi:10.1038/ng.2795. ISSN 1546-1718. PMC 3904346. PMID 24097064.
  20. ↑ "Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis". International Journal of Epidemiology. Retrieved 26 May 2022.
  21. ↑ Seeley, Janet; Nakiyingi-Miiro, Jessica; Kamali, Anatoli; Mpendo, Juliet; Asiki, Gershim; Abaasa, Andrew; De Bont, Jan; Nielsen, Leslie; Kaleebu, Pontiano (2012). "High HIV Incidence and Socio-Behavioral Risk Patterns in Fishing Communities on the Shores of Lake Victoria, Uganda". Sexually Transmitted Diseases. 39 (6): 433–439. doi:10.1097/OLQ.0b013e318251555d. ISSN 0148-5717. JSTOR 44981712. PMID 22592828. S2CID 44811502.
  22. ↑ Asiki, Gershim; Mpendo, Juliet; Abaasa, Andrew; Agaba, Collins; Nanvubya, Annet; Nielsen, Leslie; Seeley, Janet; Kaleebu, Pontiano; Grosskurth, Heiner; Kamali, Anatoli (2011). "HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda". Sexually Transmitted Infections. 87 (6): 511–515. doi:10.1136/sti.2010.046805. ISSN 1472-3263. PMID 21835763. S2CID 332068.
  23. ↑ Price, Matt A.; Wallis, Carole L.; Lakhi, Shabir; Karita, Etienne; Kamali, Anatoli; Anzala, Omu; Sanders, Eduard J.; Bekker, Linda-Gail; Twesigye, Rogers; Hunter, Eric; Kaleebu, Pontiano (1 January 2011). "Transmitted HIV Type 1 Drug Resistance Among Individuals with Recent HIV Infection in East and Southern Africa". AIDS Research and Human Retroviruses. 27 (1): 5–12. doi:10.1089/aid.2010.0030. ISSN 0889-2229. PMC 3045073. PMID 21091377.
  24. ↑ Karita, Etienne; Ketter, Nzeera; Price, Matt A.; Kayitenkore, Kayitesi; Kaleebu, Pontiano; Nanvubya, Annet; Anzala, Omu; Jaoko, Walter; Mutua, Gaudensia; Ruzagira, Eugene; Mulenga, Joseph (6 February 2009). "CLSI-Derived Hematology and Biochemistry Reference Intervals for Healthy Adults in Eastern and Southern Africa". PLOS ONE. 4 (2): e4401. Bibcode:2009PLoSO...4.4401K. doi:10.1371/journal.pone.0004401. ISSN 1932-6203. PMC 2632744. PMID 19197365.
  25. ↑ Jaoko, Walter; Nakwagala, Frederick N.; Anzala, Omu; Manyonyi, Gloria Omosa; Birungi, Josephine; Nanvubya, Annet; Bashir, Farah; Bhatt, Kirana; Ogutu, Hilda; Wakasiaka, Sabina; Matu, Lucy (23 May 2008). "Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa". Vaccine. 26 (22): 2788–2795. doi:10.1016/j.vaccine.2008.02.071. ISSN 0264-410X. PMID 18440674.
  26. ↑ Kaleebu, Pontiano; Nankya, Immaculate L.; Yirrell, David L.; Shafer, Leigh Anne; Kyosiimire-Lugemwa, Jacqueline; Lule, Daniel B.; Morgan, Dilys; Beddows, Simon; Weber, Jonathan; Whitworth, James A. G. (1 May 2007). "Relation Between Chemokine Receptor Use, Disease Stage, and HIV-1 Subtypes A and D: Results From a Rural Ugandan Cohort". Journal of Acquired Immune Deficiency Syndromes. 45 (1): 28–33. doi:10.1097/QAI.0b013e3180385aa0. ISSN 1525-4135. PMID 17310935. S2CID 11067305.
  27. ↑ Campbell, Grant R.; Pasquier, Eddy; Watkins, Jennifer; Bourgarel-Rey, Veronique; Peyrot, Vincent; Esquieu, Didier; Barbier, Pascale; Mareuil, Jean de; Braguer, Diane; Kaleebu, Pontiano; Yirrell, David L. (12 November 2004). "The Glutamine-rich Region of the HIV-1 Tat Protein Is Involved in T-cell Apoptosis *". Journal of Biological Chemistry. 279 (46): 48197–48204. doi:10.1074/jbc.M406195200. ISSN 0021-9258. PMID 15331610.
  28. ↑ "Effect of Human Immunodeficiency Virus (HIV) Type 1 Envelope Subtypes A and D on Disease Progression in a Large Cohort of HIV-1—Positive Persons in Uganda". doi:10.1086/340130. Retrieved 26 May 2022.
  29. ↑ Kaleebu, Pontiano; Ross, Amanda; Morgan, Dilys; Yirrell, David; Oram, Jon; Rutebemberwa, Alleluiah; Lyagoba, Fred; Hamilton, Laura; Biryahwaho, Benon; Whitworth, James (16 February 2001). "Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort". AIDS. 15 (3): 293–299. doi:10.1097/00002030-200102160-00001. ISSN 0269-9370. PMID 11273208. S2CID 5761147.
  30. ↑ Weber, J; Fenyö, E M; Beddows, S; Kaleebu, P; Björndal, A (1996). "Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization". Journal of Virology. 70 (11): 7827–7832. doi:10.1128/jvi.70.11.7827-7832.1996. ISSN 0022-538X. PMC 190853. PMID 8892904.
  31. ↑ Uganda Virus Research Institute. "Kaleebu Receives Medal of Service on Labour Day". Uganda Virus Research Institute. Retrieved 26 May 2022.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.